Breaking News Instant updates and real-time market news.

NKTR

Nektar

$16.79

-0.39 (-2.27%)

16:05
10/23/19
10/23
16:05
10/23/19
16:05

Nektar initiated with a Perform at Oppenheimer

Oppenheimer analyst Jay Olson initiated coverage of Nektar with a Perform rating and $18 price target.

NKTR Nektar
$16.79

-0.39 (-2.27%)

09/26/19
PIPR
09/26/19
NO CHANGE
Target $50
PIPR
Overweight
Nektar breast cancer data 'promising,' warrants more study, says Piper Jaffray
There is a large unmet need for patients with triple negative breast cancer and of all of the indications tested with checkpoint inhibitors, these patients unfortunately have one of the poorest responses to treatment, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Therefore, today's initial triple negative breast cancer that demonstrate NKTR-214 in combination with nivolumab produces a 13% overall objective response rate is "promising" and justifies additional study in future clinical trials with chemo, contends Van Buren. Also worth noting is the five responses appear durable with four of them lasting beyond one-and-a-half years relative to chemo, which typically has a short median progression-free survival of two-to-three months, adds the analyst. Van Buren, who does not currently include triple negative breast cancer in his Nektar model pending additional clinical data, keeps an Overweight rating on the shares with a $50 price target. The stock in morning trading is down 6% to $17.60.
09/30/19
HCWC
09/30/19
NO CHANGE
Target $24
HCWC
Neutral
Competitive updates bring new challenges for Nektar bulls, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay sees "fresh challenges" for bulls of Nektar Therapeutics' bempeg following competitive updates this weekend in urothelial cancer and triple-negative breast cancer. The EV-103 study, which evaluated the combination of enfortumab vedotin plus pembrolizumab in previously untreated, locally advanced or metastatic urothelial cancer, who were ineligible for cisplatin-based chemotherapy, delivered an overall response rate of 71%, Chattopadhyay tells investors in a research note. This is well above the 48% ORR reported for the bempeg plus nivolumab combination in a potentially similar patient population, adds the analyst, who keeps a Neutral rating on Nektar shares with a $24 price target.
10/08/19
GSCO
10/08/19
DOWNGRADE
Target $16
GSCO
Sell
Nektar Therapeutics downgraded to Sell from Buy at Goldman Sachs
Goldman Sachs analyst Paul Choi double downgraded Nektar Therapeutics to Sell from Buy with a price target of $16, down from $54. The stock closed Monday down 30c to $18.67. Near-term catalysts are unlikely to re-rate the stock higher in the face of quality issues and a narrower focus for bempegaldesleukin, Choi tells investors in a research note. The shares over the past 18 months have underperformed as execution missteps related to suboptimal batches overshadowed original announcements of mostly positive clinical developments, says the analyst. Even with shares down over 60% since its January 19 high, the analyst thinks uncertainty on bempeg's safety or efficacy, as well as Nektar's ability to execute on a large-scale clinical development program, will likely continue to be an overhang on shares.
10/08/19
10/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Oracle (ORCL), Carbonite (CARB), and Check Point (CHKP) downgraded to Hold from Buy at Jefferies. 2. TerraForm Power (TERP) downgraded to Equal Weight from Overweight at Barclays. 3. Puma Biotechnology (PBYI) downgraded to Sell from Neutral at Goldman Sachs while Nektar Therapeutics (NKTR) was double downgraded to Sell from Buy. 4. Qiagen (QGEN) downgraded to Underweight from Neutral at JPMorgan and to Equal Weight from Overweight at Barclays. 5. Helmerich & Payne (HP) and Patterson-UTI (PTEN) downgraded to Neutral from Buy at BofA/Merrill. Nine Energy Services (NINE) and FTS International (FTSI) downgraded to Underperform from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

QGEN

Qiagen

$37.39

0.085 (0.23%)

15:39
11/15/19
11/15
15:39
11/15/19
15:39
Hot Stocks
Breaking Hot Stocks news story on Qiagen »

Qiagen shares up 8% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

QGEN

Qiagen

$37.39

0.085 (0.23%)

15:38
11/15/19
11/15
15:38
11/15/19
15:38
Hot Stocks
Breaking Hot Stocks news story on Qiagen 

Qiagen trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

XLB

S&P Select Materials SPDR

$60.24

-0.18 (-0.30%)

, XLV

Health Care Select Sector SPDR

$97.52

2.12 (2.22%)

15:38
11/15/19
11/15
15:38
11/15/19
15:38
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

At time of writing the…

XLB

S&P Select Materials SPDR

$60.24

-0.18 (-0.30%)

XLV

Health Care Select Sector SPDR

$97.52

2.12 (2.22%)

XLK

Technology Select Sector SPDR

$86.97

0.4 (0.46%)

XLY

Consumer Discretionary Sector SPDR

$121.21

0.09 (0.07%)

XLE

Energy Select Sector SPDR

$59.96

0.35 (0.59%)

SPY

SPDR S&P 500 ETF Trust

$311.23

1.7 (0.55%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$77.58

0.71 (0.92%)

, WE

We Company

$0.00

(0.00%)

15:35
11/15/19
11/15
15:35
11/15/19
15:35
Periodicals
T-Mobile CEO Legere not taking top job at WeWork, CNBC reports »

T-Mobile (TMUS) Chief…

TMUS

T-Mobile

$77.58

0.71 (0.92%)

WE

We Company

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

S

Sprint

$5.84

-0.025 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 09

    Dec

TMUS

T-Mobile

$77.61

0.74 (0.96%)

15:31
11/15/19
11/15
15:31
11/15/19
15:31
Hot Stocks
Breaking Hot Stocks news story on T-Mobile »

T-Mobile up 2% to $78.47…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 09

    Dec

TMUS

T-Mobile

$77.62

0.75 (0.98%)

, WE

We Company

$0.00

(0.00%)

15:31
11/15/19
11/15
15:31
11/15/19
15:31
Periodicals
Breaking Periodicals news story on T-Mobile, We Company »

T-Mobile CEO Legere not…

TMUS

T-Mobile

$77.62

0.75 (0.98%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 09

    Dec

CNI

Canadian National

$93.67

0.49 (0.53%)

15:28
11/15/19
11/15
15:28
11/15/19
15:28
Periodicals
CNI laying off 1,600 workers on volume declines, Globe and Mail reports »

Canadian National Railway…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 21

    Nov

  • 22

    Nov

QGEN

Qiagen

$37.48

0.175 (0.47%)

, TMO

Thermo Fisher

$306.50

5.68 (1.89%)

15:24
11/15/19
11/15
15:24
11/15/19
15:24
Hot Stocks
Qiagen exploring alternatives after receiving 'several' indications of interest »

Qiagen (QGEN) announced…

QGEN

Qiagen

$37.48

0.175 (0.47%)

TMO

Thermo Fisher

$306.50

5.68 (1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 07

    Dec

QGEN

Qiagen

$37.50

0.195 (0.52%)

15:22
11/15/19
11/15
15:22
11/15/19
15:22
Hot Stocks
Breaking Hot Stocks news story on Qiagen »

Qiagen decides to enter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

15:20
11/15/19
11/15
15:20
11/15/19
15:20
General news
Treasury Market Summary »

Treasury Market Summary:…

TMO

Thermo Fisher

$306.76

5.94 (1.97%)

, QGEN

Qiagen

$37.51

0.205 (0.55%)

15:18
11/15/19
11/15
15:18
11/15/19
15:18
Hot Stocks
Breaking Hot Stocks news story on Thermo Fisher, Qiagen »

Thermo Fisher up 2% to…

TMO

Thermo Fisher

$306.76

5.94 (1.97%)

QGEN

Qiagen

$37.51

0.205 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 07

    Dec

NVS

Novartis

$90.12

0.6 (0.67%)

15:18
11/15/19
11/15
15:18
11/15/19
15:18
Hot Stocks
Novartis confirms Adakveo approved by FDA »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AGTC

Applied Genetic

$2.76

-0.125 (-4.33%)

15:17
11/15/19
11/15
15:17
11/15/19
15:17
Conference/Events
Applied Genetic management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 04

    Dec

QGEN

Qiagen

$37.48

0.175 (0.47%)

15:17
11/15/19
11/15
15:17
11/15/19
15:17
Hot Stocks
Breaking Hot Stocks news story on Qiagen »

Qiagen trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
11/15/19
11/15
15:17
11/15/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
11/15/19
11/15
15:16
11/15/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$133.46

2.48 (1.89%)

15:00
11/15/19
11/15
15:00
11/15/19
15:00
Periodicals
Oklahoma judge cuts J&J payment due in opioid case to $465M, Reuters reports »

An Oklahoma judge has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

EA

Electronic Arts

$97.88

0.34 (0.35%)

14:59
11/15/19
11/15
14:59
11/15/19
14:59
Periodicals
EA, BioWare planning complete revamp of 'Anthem,' Kotaku says »

Video game developer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

F

Ford

$8.95

0.15 (1.70%)

, GM

General Motors

$36.92

0.12 (0.33%)

14:56
11/15/19
11/15
14:56
11/15/19
14:56
Periodicals
States sue EPA for right for stricter emission regulations, Washington Post says »

California, along with 23…

F

Ford

$8.95

0.15 (1.70%)

GM

General Motors

$36.92

0.12 (0.33%)

HMC

Honda

$29.01

0.175 (0.61%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$144.15

1.02 (0.71%)

TSLA

Tesla

$350.80

1.29 (0.37%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.03

0.05 (0.31%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 09

    Dec

  • 04

    Feb

MDLZ

Mondelez

$52.71

-0.19 (-0.36%)

14:52
11/15/19
11/15
14:52
11/15/19
14:52
Hot Stocks
Mondelez recalls Cheese Nips in U.S. due to potential presence of plastic pieces »

Mondelez Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COLM

Columbia Sportswear

$93.21

-1.28 (-1.35%)

14:50
11/15/19
11/15
14:50
11/15/19
14:50
Conference/Events
Columbia Sportswear participates in a conference call with Wedbush »

Footwear & Apparel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

14:47
11/15/19
11/15
14:47
11/15/19
14:47
Conference/Events
Wedbush hardware/component analyst to hold an analyst/industry conference call »

Hardware & Component…

NVS

Novartis

$89.84

0.32 (0.36%)

14:43
11/15/19
11/15
14:43
11/15/19
14:43
Hot Stocks
Novartis receives FDA approval for BLA for Adakveo injection »

The FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ALNA

Allena Pharmaceuticals

$1.61

-0.03 (-1.83%)

14:39
11/15/19
11/15
14:39
11/15/19
14:39
Conference/Events
Wedbush emerging pharma analyst to hold an analyst/industry conference call »

Emerging Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$138.00

3.53 (2.63%)

, CYH

Community Health

$2.95

0.075 (2.61%)

14:38
11/15/19
11/15
14:38
11/15/19
14:38
Hot Stocks
Hospital stocks up after Trump reveals healthcare price transparency proposal »

Shares of several…

HCA

HCA Healthcare

$138.00

3.53 (2.63%)

CYH

Community Health

$2.95

0.075 (2.61%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$142.53

1.36 (0.96%)

THC

Tenet

$29.91

0.44 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.